Aclaris Therapeutics, Inc.
ACRSHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Aclaris Therapeutics, Inc. focuses on Biotechnology services and products. Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United. At a $552.0M market cap, Aclaris Therapeutics, Inc. ranks as a small-cap company within healthcare. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various di.
Market Cap
$552.0M
Beta
0.88
P/E (TTM)
—
P/E (Fwd)
-4.78
EPS (TTM)
$-0.57
EPS (Fwd)
$-0.78
ROE
-59.1%
ROA
-29.0%
Cash
$91.6M
Total Debt
$1.9M
Free CF
-$42.0M
52W Change
74.4%
Annual Financials
Cash vs Debt
Where ACRS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ACRS finished 28.54% below its 150-day moving average ($4.87) and 22.32% below its 200-day moving average ($4.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACRS overbought or oversold?
At the October 20, 2026 close, ACRS's RSI(14) was 22.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aclaris Therapeutics, Inc. holds $91.6M in cash against $1.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$42.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -59.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $29.8M (2022) to $7.8M (2025), a 74% decline worth watching.
With cash comfortably exceeding debt, ACRS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aclaris Therapeutics, Inc.'s trajectory.